Fewer than 10% of HCV patients finish tx
Few patients with hepatitis C virus infection complete all of the steps along a proposed HCV treatment cascade, according to a systematic literature review and meta-analysis.
MOC took center stage at AMA Congress
The American Medical Association should continue to work with the American Board of Medical Specialties to address physicians’ concerns about Maintenance of Certification – that was the consensus at the annual meeting of the AMA House of Delegates.
Anti-TNFs didn’t increase cancer in IBD
The tumor necrosis factor–alpha antagonists infliximab, adalimumab, and certolizumab did not raise the risk of cancer in a nationwide Danish cohort study of patients with inflammatory bowel disease who were followed for approximately 10 years, according to a report published online in JAMA.
CMS details fee schedule, care coordination pay
Starting Jan. 1, 2015, Medicare will pay physicians about $42 for certain care management services outside of the face-to-face office visit, according to a new government proposal.
Sofosbuvir achieves SVR12 in patients with HCV + HIV
Treatment with the interferon-free oral nucleotide analog sofosbuvir plus ribavirin achieved high rates of sustained virologic response in patients with HIV coinfected with hepatitis C, according to data from an open-label phase III study.